CG 858-Neg

Overview

CG 858-Neg (compound 13) is a negative control for Thalidomide ( HY-14658 )-derived PROTAC degraders, targeting BRAF and BRAF V600E with K i values ​​of 9.5 nM and 14.4 nM, respectively. CG 858-Neg inhibits downstream ERK phosphorylation and suppresses BRAF V600E -driven melanoma (e.g., A375 cells, IC 50 =492 nM) and colorectal cancer (e.g., HT-29 cells, IC 50 =459 nM) cells. CG 858-Neg can be used in research related to melanoma and colorectal cancer .

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Melanoma | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer Immunology | Products > Disease Areas > Immunotherapy for Melanoma | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Ligands for E3 Ligase | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Raf

Product Information

• Catalog No.: HY-180329
• CAS No.: 2417296-83-2
• Molecular Formula: C43H41F2N7O8S
• Molecular Weight: 853.89
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source